DEFA14A: Globalink, Alps Holdco Amend Merger Terms, Extend Consent

Globalink Investment Inc. and Alps Life Sciences Inc. have amended their merger agreement, adjusting escrow share contributions and extending the Alps Holdco shareholder consent deadline.

Summary

• Globalink Investment Inc. and Alps Life Sciences Inc. (Alps Holdco) entered into a Third Amendment to their Amended and Restated Merger Agreement on September 27, 2025.
• The amendment allows Dr. Tham Seng Kong, in his personal capacity, to contribute all Escrow Shares from his personal entitlement of Merger Consideration Shares.
• The Alps Holdco Shareholder Written Consent Deadline has been extended to be as promptly as reasonably practicable after the F-4 Effective Date and in any event prior to the Effective Time.
• The Escrow Agreement will now stipulate that 5% of the Merger Consideration, with each share valued at $10.00, will be held in a segregated escrow account.
• The Escrow Property will be released and transferred solely to Dr. Tham Seng Kong as the contributing Alps Holdco Shareholder and will serve as the sole source of payment for Alps Holdco Shareholder obligations under Article XII of the agreement.
• Indemnification claims against the Escrow Property are not subject to claims made after six months following the Closing Date, with provisions for pending claims.

Sentiment

Score: 6

Explanation: The amendment is a necessary step to advance the merger, addressing specific terms and extending a deadline. While the deadline extension introduces a minor concern, the overall action aims to facilitate the transaction's completion, which is generally positive for deal progression.

Positives

• The amendment facilitates the progression of the proposed business combination by addressing specific terms related to escrow and shareholder consent.
• Dr. Tham Seng Kong's personal contribution of escrow shares demonstrates a commitment to the transaction.

Negatives

• The extension of the Alps Holdco Shareholder Written Consent Deadline could indicate unforeseen complexities or delays in obtaining necessary approvals.
• Concentration of the escrow risk and benefit solely on Dr. Tham Seng Kong, while simplifying the process, shifts potential liabilities to a single individual.

Risks

• The proposed transactions may not be consummated within the anticipated time period, or at all.
• Globalink may fail to obtain stockholder approval of the proposed business combination.
• The parties may fail to secure required regulatory approvals under applicable laws.
• Other conditions to the consummation of the proposed transactions under the Merger Agreement may not be satisfied.
• Termination of the Merger Agreement could lead to a significant decline in Globalink's stock price.
• The announcement or pendency of the proposed transactions may disrupt PubCo's, Globalink's, or Alps Holdco's current plans and operations.
• Inability to recognize the anticipated benefits of the proposed transactions.
• Unexpected costs resulting from the proposed transactions.
• Changes in general economic conditions, regulatory conditions and developments, or applicable laws or regulations.
• The nature, cost, and outcome of pending and future litigation and other legal proceedings, including those related to the proposed transactions.

Future Outlook

The parties continue to work towards the consummation of the proposed business combination, which is subject to various conditions including Globalink's stockholder approval and required regulatory approvals. The amendment aims to facilitate these processes, but actual results may differ materially from forward-looking statements due to numerous risks and uncertainties.

Management Comments

• Say Leong Lim, Chairman & CEO of Globalink Investment Inc., signed the Third Amendment.
• Dr. Tham Seng Kong, representing Alps Life Sciences Inc. and as the Seller Representative, signed the Third Amendment.

Industry Context

This amendment is a typical procedural step in the complex process of a SPAC (Special Purpose Acquisition Company) business combination, where terms are often adjusted to address unforeseen issues or facilitate deal closure. Such amendments are common in transactions involving private companies merging with publicly traded SPACs, reflecting ongoing negotiations and regulatory compliance efforts.

Corporate Governance

Related Party Transactions

• Dr. Tham Seng Kong, in his personal capacity and also as the Seller Representative, will contribute all Escrow Shares from his personal entitlement of Merger Consideration Shares, and the Escrow Property will be released solely to him.

Stakeholder Impact

• Globalink shareholders: Will need to read the proxy statement/prospectus and vote on the proposed business combination.
• Alps Holdco shareholders: Required to provide written consent, with Dr. Tham Seng Kong acting as their representative.
• Dr. Tham Seng Kong: Bears the direct responsibility and benefit related to the Escrow Shares and is the sole recipient of the Escrow Property upon release.

Next Steps

• PubCo to file a registration statement on Form F-4, including a proxy statement/prospectus, with the SEC.
• Globalink's stockholders to vote on the proposed business combination.
• Alps Holdco to obtain and deliver the Alps Holdco Shareholder Written Consent prior to the Effective Time.
• The parties to secure required regulatory approvals under applicable laws.
• The closing of the proposed transactions, subject to all conditions being satisfied.

Key Dates

Recommendation

This filing details an amendment to an ongoing merger agreement, which is a procedural step to facilitate the transaction. While the extension of a deadline could be a minor negative signal, the overall intent is to move the deal forward. There are no new financial results or significant strategic shifts to warrant a strong buy or sell recommendation. Investors should hold their position pending further developments and the ultimate completion of the merger, while carefully considering the outlined risks.

Keywords

Globalink Investment Inc., Alps Life Sciences Inc., Merger Agreement, Business Combination, SEC Filing, DEFA14A, Escrow Shares, Shareholder Consent, SPAC, Corporate Governance